Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study
ConclusionThis study suggests that second-line fluoropyrimidine-based regimens after N + G failure are feasible, have a manageable toxicity profile in selected patients with MPA, and are associated with promising clinical outcomes, in particular when combined with irinotecan. Randomized phase 3 trials are needed to confirm this trend.
Source: Clinics and Research in Hepatology and Gastroenterology - Category: Gastroenterology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | France Health | Gastroenterology | Pancreas | Pancreatic Cancer | Study | Toxicology